AUPR878201A0 - New compounds - Google Patents

New compounds

Info

Publication number
AUPR878201A0
AUPR878201A0 AUPR8782A AUPR878201A AUPR878201A0 AU PR878201 A0 AUPR878201 A0 AU PR878201A0 AU PR8782 A AUPR8782 A AU PR8782A AU PR878201 A AUPR878201 A AU PR878201A AU PR878201 A0 AUPR878201 A0 AU PR878201A0
Authority
AU
Australia
Prior art keywords
new compounds
compounds
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPR8782A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Priority to AUPR8782A priority Critical patent/AUPR878201A0/en
Publication of AUPR878201A0 publication Critical patent/AUPR878201A0/en
Priority to TW091124998A priority patent/TWI300713B/zh
Priority to ES02779943T priority patent/ES2325318T3/es
Priority to AT02779943T priority patent/ATE427940T1/de
Priority to DE60231897T priority patent/DE60231897D1/de
Priority to PCT/JP2002/011314 priority patent/WO2003040110A1/en
Priority to PT02779943T priority patent/PT1442026E/pt
Priority to JP2003542156A priority patent/JP3972208B2/ja
Priority to CNB028269004A priority patent/CN100338042C/zh
Priority to EP02779943A priority patent/EP1442026B9/en
Priority to KR10-2003-7002474A priority patent/KR100511884B1/ko
Priority to DK02779943T priority patent/DK1442026T3/da
Priority to CA2465757A priority patent/CA2465757C/en
Priority to US10/344,416 priority patent/US6927230B2/en
Priority to ARP020104295A priority patent/AR037347A1/es
Priority to JP2007024703A priority patent/JP2007169290A/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AUPR8782A 2001-11-09 2001-11-09 New compounds Abandoned AUPR878201A0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AUPR8782A AUPR878201A0 (en) 2001-11-09 2001-11-09 New compounds
TW091124998A TWI300713B (en) 2001-11-09 2002-10-25 Triazole derivatives
US10/344,416 US6927230B2 (en) 2001-11-09 2002-10-30 Triazole derivatives
PT02779943T PT1442026E (pt) 2001-11-09 2002-10-30 Derivados de triazole como inibidores de ciclooxigenases (coxs)
EP02779943A EP1442026B9 (en) 2001-11-09 2002-10-30 Triazole derivatives as cyclooxygenase (cox) inhibitors
DE60231897T DE60231897D1 (de) 2001-11-09 2002-10-30 Triazol derivate als cyclooxygenase inhibitoren
PCT/JP2002/011314 WO2003040110A1 (en) 2001-11-09 2002-10-30 Triazole derivatives as cyclooxygenase (cox) inhibitors
ES02779943T ES2325318T3 (es) 2001-11-09 2002-10-30 Derivados de triazol como inhibidores de la ciclooxigenasa (cox).
JP2003542156A JP3972208B2 (ja) 2001-11-09 2002-10-30 トリアゾール誘導体
CNB028269004A CN100338042C (zh) 2001-11-09 2002-10-30 作为环加氧酶(cox)抑制剂的三唑衍生物
AT02779943T ATE427940T1 (de) 2001-11-09 2002-10-30 Triazol derivate als cyclooxygenase inhibitoren
KR10-2003-7002474A KR100511884B1 (ko) 2001-11-09 2002-10-30 트리아졸 유도체
DK02779943T DK1442026T3 (da) 2001-11-09 2002-10-30 Triazolderivater som cyclooxygenase (COX)-inhibitorer
CA2465757A CA2465757C (en) 2001-11-09 2002-10-30 Triazole derivatives as cyclooxygenase (cox) inhibitors
ARP020104295A AR037347A1 (es) 2001-11-09 2002-11-08 Derivados de triazol
JP2007024703A JP2007169290A (ja) 2001-11-09 2007-02-02 トリアゾール誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPR8782A AUPR878201A0 (en) 2001-11-09 2001-11-09 New compounds

Publications (1)

Publication Number Publication Date
AUPR878201A0 true AUPR878201A0 (en) 2001-12-06

Family

ID=3832601

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPR8782A Abandoned AUPR878201A0 (en) 2001-11-09 2001-11-09 New compounds

Country Status (15)

Country Link
US (1) US6927230B2 (https=)
EP (1) EP1442026B9 (https=)
JP (2) JP3972208B2 (https=)
KR (1) KR100511884B1 (https=)
CN (1) CN100338042C (https=)
AR (1) AR037347A1 (https=)
AT (1) ATE427940T1 (https=)
AU (1) AUPR878201A0 (https=)
CA (1) CA2465757C (https=)
DE (1) DE60231897D1 (https=)
DK (1) DK1442026T3 (https=)
ES (1) ES2325318T3 (https=)
PT (1) PT1442026E (https=)
TW (1) TWI300713B (https=)
WO (1) WO2003040110A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055502A1 (en) * 2001-01-02 2002-07-18 Fujisawa Pharmaceutical Co., Ltd. Pyridine derivatives useful as cyclooxygenase inhibitor
AUPR878201A0 (en) * 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds
KR100470076B1 (ko) 2002-11-27 2005-02-05 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
KR20050083761A (ko) 2002-12-02 2005-08-26 후지사와 야꾸힝 고교 가부시키가이샤 Ｃｏｘ－ｉ저해제로서 유용한 피라졸 유도체
WO2004060367A1 (en) * 2002-12-30 2004-07-22 Fujisawa Pharmaceutical Co., Ltd. Imidazole and triazole derivatives useful as selective cox-1 inhibitors
KR20050096956A (ko) 2003-02-07 2005-10-06 다이이찌 세이야꾸 가부시기가이샤 피라졸 유도체
WO2004099130A2 (en) * 2003-05-08 2004-11-18 Astellas Pharma Inc. 1,2-diarylimidazoles useful as inhibitors of cox
ZA200703562B (en) * 2004-10-19 2008-08-27 Daiichi Seiyaku Co 1,5-diheterocycle-1H-triazole derivative
BRPI0908584A2 (pt) * 2008-04-01 2015-09-15 Astellas Pharma Inc agente para prevenir e/ou tratar doenças vasculares
US20130137739A1 (en) * 2010-05-31 2013-05-30 Astellas Pharma, Inc. Solid dispersion comprising triazole compound
UA112418C2 (uk) * 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
KR101178947B1 (ko) * 2011-04-29 2012-09-03 한국생명공학연구원 올레아놀린산 아세테이트를 유효성분으로 포함하는 ｔｌｒ 및 ｉｌ-6 매개성 질환 예방 또는 치료용 약학적 조성물
WO2012170839A2 (en) * 2011-06-09 2012-12-13 Cardeus Pharmaceuticals, Inc. Treatment of neuroinflammatory disease with selective cox1 inhibitors
BR112015010504A2 (pt) 2012-11-09 2017-12-05 Univ Cornell uso de inibidores de molécula pequena de malt1, método de identificação de um modulador de molécula pequena de malt1, e composição farmacêutica
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
CN115611901B (zh) * 2021-07-16 2024-04-30 华南理工大学 一种氮杂䓬类化合物或其药学上可接受的盐及其制备方法和应用
EP4525983A4 (en) 2022-05-16 2025-09-03 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0051084A1 (en) 1980-11-04 1982-05-12 American Cyanamid Company Substituted 1H-1,2,4-triazoles
HU193891B (en) * 1984-02-07 1987-12-28 Gyogyszerkutato Intezet Process for production of new derivatives of 1,2,4-triasole
FI850995L (fi) 1984-03-16 1985-09-17 Ciba Geigy Ag Foerfarande foer framstaellning av nya 3-merkapto-1,2,4-triazacykloalkadienderivat.
FI850994A7 (fi) * 1984-03-16 1985-09-17 Ciba Geigy Ag Menetelmä uusien 1,2,4 -triatsasykloalkadieenijohdannaisten valmistamiseksi.
AU581216B2 (en) 1984-04-17 1989-02-16 Henkel Corporation Production of d-alpha-tocopherol from natural plant sources
JPS60233066A (ja) * 1984-05-07 1985-11-19 Nippon Nohyaku Co Ltd １．５−ジフエニルトリアゾ−ル誘導体及びその製造方法
WO1999051580A1 (en) 1998-04-08 1999-10-14 Abbott Laboratories Pyrazole inhibitors of cytokine production
JP2003525201A (ja) 1998-08-20 2003-08-26 スミスクライン・ビーチャム・コーポレイション 新規な置換トリアゾール化合物
EP1099695A1 (en) 1999-11-09 2001-05-16 Laboratoire Theramex S.A. 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
AUPR878201A0 (en) * 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds

Also Published As

Publication number Publication date
ES2325318T3 (es) 2009-09-01
ATE427940T1 (de) 2009-04-15
KR100511884B1 (ko) 2005-09-05
EP1442026A1 (en) 2004-08-04
KR20030060878A (ko) 2003-07-16
JP2004521964A (ja) 2004-07-22
EP1442026B9 (en) 2009-11-18
CN1612865A (zh) 2005-05-04
CN100338042C (zh) 2007-09-19
DE60231897D1 (de) 2009-05-20
EP1442026B1 (en) 2009-04-08
AR037347A1 (es) 2004-11-03
US6927230B2 (en) 2005-08-09
WO2003040110A1 (en) 2003-05-15
PT1442026E (pt) 2009-06-25
JP2007169290A (ja) 2007-07-05
JP3972208B2 (ja) 2007-09-05
DK1442026T3 (da) 2009-07-06
CA2465757A1 (en) 2003-05-15
TWI300713B (en) 2008-09-11
US20030191155A1 (en) 2003-10-09
CA2465757C (en) 2011-11-29

Similar Documents

Publication Publication Date Title
AU2002349297A1 (en) Statin-like compounds
AU2002360508A1 (en) Substituted hydroxyethylamines
AU2002359165A1 (en) Novel compounds
AUPR878201A0 (en) New compounds
AU2002300754A1 (en) New Combination
AU2002251024A1 (en) Substituted fluoroalcoxyphenylsulfonylurea
AUPR362001A0 (en) New compound
AU2002321215A1 (en) Substituted 4-aminocyclohexanols
AUPR920301A0 (en) Neurologically-active compounds
AU2002226571A1 (en) Biligands
AU2001100406A4 (en) DriverSMS
AU2004201666B2 (en) 4-Imidazolin-2-one compounds
AU2002255414A1 (en) New compounds
HK1060725A (en) New compounds
AU2002316006A1 (en) New compounds
AUPR300701A0 (en) New compounds
AUPR669701A0 (en) New compounds
AUPR775701A0 (en) New compounds
AU2002257925A1 (en) Numberplates
AU2002306300A1 (en) Azasugar compounds
AU2002337136A1 (en) Isocyanato-isocyano compounds
AU2002235881A1 (en) Compounds
AU2002363108A1 (en) 4-imidazolin-2-one compounds
AU2002346861A1 (en) Substituted 1h-quinolin-2-one compounds
AUPR336401A0 (en) New compound